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a b s t r a c t
Type 2 diabetes mellitus (T2DM), by deﬁnition is a heterogeneous, multifactorial, polygenic syndrome
which results from insulin receptor dysfunction. It is an outcome of oxidative stress caused by
interactions of reactive metabolites (RMs) interactions with lipids, proteins and other mechanisms of
human body. Production of RMs mainly superoxide (Od2 ) has been found in a variety of predominating
cellular enzyme systems including NAD(P)H oxidase, xanthine oxidase (XO), cyclooxygenase (COX),
uncoupled endothelial nitric oxide synthase (eNOS) and myeloperoxidase (MPO). The four main RM
related molecular mechanisms are: increased polyol pathway ﬂux; increased advanced glycation end-
product (AGE) formation; activation of protein kinase C (PKC) isoforms and increased hexosamine
pathway ﬂux which have been implicated in glucose-mediated vascular damage. Superoxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase (GST), nitric oxide
synthase (NOS) are antioxidant enzymes involved in scavenging RMs in normal individuals. Functional
polymorphisms of these antioxidant enzymes have been reported to be involved in pathogenesis of
T2DM individuals. The low levels of antioxidant enzymes or their non-functionality results in excessive
RMs which initiate stress related pathways thereby leading to insulin resistance and T2DM. An attempt
has been made to review the role of RMs and antioxidant enzymes in oxidative stress resulting in T2DM.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.
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Introduction
Diabetes Mellitus (DM) is a chronic disorder characterized by
impaired metabolism of glucose and lipids due to defect in insulin
secretion (beta cell dysfunction) or action (insulin resistance).
The characteristic properties of diabetes mellitus are chronic
hyperglycemia, microvascular (eg. retina, renal glomerulus and
peripheral nerve) as well as macrovascular (eg. atherosclerosis,
coronary artery disease (CAD), stroke) pathologies with more than
17.5 million deaths worldwide attributable to cardiovascular
complications [1]. According to International Diabetes Federation
(IDF) Diabetes Atlas 5th Edition-2012 update, 371 million people
have been reported with DM and the number is expected to rise to
4552 million by 2030. The 2012 Indian statistics showed 63.0
million diabetic cases and a prevalence of 8.37% in adult popula-
tion [2] while a 4.0% prevalence of type 2 diabetes mellitus (T2DM)
was reported in North Indian population [3]. The currently favored
hypothesis is oxidative stress leading to insulin resistance (IR), β-
cell dysfunction, impaired glucose tolerance (IGT) and ultimately
T2DM. Furthermore, oxidative stress has been implicated as the
underlying cause of both macrovascular and microvascular com-
plications associated with T2DM. It is believed that therapies
aimed at reducing oxidative stress would beneﬁt patients with
T2DM and also those at risk. The accumulation of glucose and fatty
acids within muscles, adipose tissue and pancreatic cells combined
with sedentary lifestyle lead to the generation of excess reactive
metabolites (RMs). Oxidative stress and RMs are interrelated terms
deﬁned in general as excess formation and/or insufﬁcient removal
of highly reactive molecules such as reactive oxygen species (ROS),
reactive nitrogen species (RNS) and reactive thiyl species (RTR).
This review aims to explain the role of such RMs and association of
antioxidant gene polymorphisms with T2DM.
Types of reactive metabolites (RMs)
ROS: oxygen derived free radicals (ODFR) and oxygen derived non
radicals (ODNR)
Oxygen derived free radical and non-radical reactive species
are generated in metabolic pathways of biological systems. ODFR
include superoxide (Od2 ), hydroxyl (
dOH), peroxyl (dRO2), hydro-
peroxyl dHRO2 Þ

while ODNR include hydrogen peroxide (H2O2)
and hydrochlorous acid (HOCl). These metabolites are responsible
for lipid and protein modiﬁcations in case of oxidative stress [4].
Basal oxidative cellular metabolism generates a number of oxygen-
derived free radical species through the activation of enzymes that
produce superoxide anions and/or byproducts of mitochondrial
respiration [5].
Reactive nitrogen species (RNS): nitrogen derived free radicals (NDFR)
and nitrogen derived non radicals (NDNR)
Like ROS, RNS can be classiﬁed into radical and non-radical
species. NDFR include nitric oxide (dNO), nitrogen dioxide (dNO2 )
while NDNR include alkyl peroxynitrates (RONOO), nitrous oxide
(HNO2) and peroxynitrite (ONOO). O
d
2 ,
dNO and ONOO are the
most widely studied species and play important roles in cardio-
vascular complications [5]. Nitric oxide (dNO) is responsible for
formation of many end-products involved in oxidative stress
directly or indirectly after reaction with oxygen. dNO-derived
RNS react with aromatic amino acids, lipids and thiols resulting
in lipid and protein modiﬁcations [4]. Leukocyte peroxidases are
involved in the formation of dNO2 after utilization of H2O2
and NO2 as substrates.
dNO2, dOH and ONOOH are responsible
for damages related to oxidative stress eg. oxidation, nitrosation
and nitration reactions [5,6].
Reactive thiyl and tyrosyl radicals (RTR)
RMs play a major role in generation of thiyl radicals (RSd) and
their derivatives, sulﬁnyl (RSOd) and disulﬁde anion radical
(RSSRd) [7]. ROS and RNS induce protein S-glutathionylation
either by protein thiol oxidative/nitrosative modiﬁcation or by
presence of protein thiyl radical (R–Sd), sulfenic acid (R–SOH) and
S-nitrosothiol (R–SNO) [7]. Thiyl radicals (TR) may be formed
by dOH, ONOO and/or Fe3þ mediated oxidation of thiols. TR
may also be derived from sulfur containing moieties including
disulﬁde, thioester or thioether functionalities under conditions of
oxidative stress. Once formed, TR not only reacts with themselves
and oxygen but also oxidize biological electron donors including
ascorbic acid, NADH and ferricytochrome C. Myeloperoxidase uses
H2O2 generated by the cells to oxidize L-tyrosine to tyrosyl radical.
RTR radical initiates lipid peroxidation which may be of pivotal
importance in transforming low density lipoprotein (LDL) into
atherogenic particles [8]. Glutathione (GSH) is a tripeptide,
γ-glutamyl-L-cysteinylglycine detected in all mammalian tissues
and is present in disulﬁde form of glutathione (GSSG) [9].
Thiol status/redox balance determined by redox pair 2GSH/GSSG
is an indicator of redox homeostasis or oxidative stress inside the
cell. S-glutathionylation has been proposed as a posttranslational
modiﬁcation which is able to protect proteins from over-oxidizing
environments in a wide range of diseases including diabetes
mellitus [9].
Production of reactive metabolites (RMs)
Production of RMs mainly superoxides (Od2 ) have been found
in a variety of predominating cellular enzyme systems including
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase,
xanthine oxidase (XO), cyclooxygenase (COX), uncoupled endothe-
lial nitric oxide synthase (eNOS) and myeloperoxidase (MPO) [10]
(Table 1). The various sources of ROS and action of antioxidant
enzymes have been represented in Fig. 1. NADPH oxidase uses
NADPH as a substrate and is considered as an important source of
ROS generation in vascular cells [4]. The lipoxygenase (LPO) and
COX generate ROS indirectly by promoting formation of inﬂam-
matory mediators. RM production may result from action of
arachidonic acid metabolizing enzymes including cytochrome
P-450, LPO, COX and those in the mitochondrial respiratory chain
[11]. Arachidonic acid (AA) is cleaved from the membrane by
phospholipase A2 (PLA2) and is then metabolized by 5-LPO in the
presence of its accessory protein 5-lipoxygenase activating protein
(FLAP) to form leukotrienes (LTs) [12]. AA is also metabolized by
COX to form members of another family of inﬂammatory media-
tors, the prostaglandins (PGs) [12]. Mitochondria also generate
superoxides as electrons are transferred from complexes I to IV
during normal cellular respiration. XO, which converts hypox-
anthine and xanthine to uric acid, is an additional source of ROS
[12]. Finally, eNOS uncouples to generate superoxide in preference
to NO [13].
Reactive metabolites and Type 2 diabetes mellitus
There are four main molecular mechanisms implicated in
glucose-mediated vascular damage viz. increased polyol pathway
ﬂux; increased production of advanced glycation end-product
(AGE); activation of protein kinase C (PKC) isoforms, sorbitol,
cytokines and prostanoids along with increased hexosamine
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pathway ﬂux [16,17] (Fig. 2). Od2 leads to several damaging
pathways resulting in micro and macrovascular complications in
diabetes which accelerates the formation of advanced glycation
end products (AGE), polyol pathway and phospholipase C (PLC)
[16,17]. Od2 and H2O2 stimulate stress-related signaling mechan-
isms such as nuclear factor kappa light chain enhancer of activated
B cells (NF-κB), mitogen activated protein kinase (p38-MAPK)
and janus kinase signal transducer and activator of transcription
(JAK-STAT) resulting in vascular smooth muscle cell (VSMC)
migration and proliferation [16]. H2O2 also mediates apoptosis
and pathological angiogenesis in endothelial cells [6]. Pathway-
selective insulin resistance also results in decreased endothelial
production of the anti-atherogenic molecule, nitric oxide [17].
Additional stress-sensitive kinases that are reported to be
involved in insulin receptor substrate (IRS)-mediated insulin
resistance include several isozymes of protein kinase C (PKC) such
as PKCβ, PKCγ and inhibitor kinase beta NF-κB (IKKβ-NFκB)
[16,18]. Once activated, these kinases are able to phosphorylate
multiple targets including insulin receptors and IRS proteins such
as IRS-1 and IRS-2. Oxidative stress activates serine kinases by
various molecular mechanisms resulting in phosphorylation of
serine in IRS, which induces insulin resistance [19,20]. This reﬂects
decreased activity of vasodilators such as nitric oxide, increased
activity of vasoconstrictors such as angiotensin II and endothelin-1
and elaboration of permeability factors such as vascular endothe-
lial growth factor (VEGF) [16,21]. Quantitative and qualitative
abnormalities of extracellular matrix contribute to an irreversible
increase in vascular permeability. Microvascular cell loss occurs
with time as a result of programmed cell death and progressive
capillary occlusion. Both occur due to extracellular matrix and
overproduction induced by growth factors such as transforming
growth factor-β (TGF-β) and deposition of plasma proteins
[13,16,21].
A causative link among hyperglycemia, mitochondrial ROS
generation, oxidative stress and development of complications
has been suggested which plays a key role in the pathogenesis
Fig. 1. Outline of various sources of reactive oxygen species (ROS) and action of antioxidant enzymes. Superoxide anion Od2 is formed by several metabolic and enzymatic
sources within the cell. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase uses NADPH as a substrate, and is considered an important source of ROS. The
lipoxygenases (LO) and cyclooxygenases (COX) generate ROS indirectly by promoting formation of inﬂammatory mediators. Arachidonic acid (AA) cleaved from the
membrane by phospholipase A2 (PLA2) is metabolized by 5-LO in the presence of accessory protein (FLAP) to form leukotrienes (LTs). Mitochondria also generate superoxide
as electrons are transferred from complexes I to IV during normal cellular respiration. Xanthine oxidase (XO), which converts hypoxanthine and xanthine to uric acid is an
additional source of ROS. Finally, endothelial nitric oxide synthase (eNOS) uncouples to generate superoxide in preference to NO. Q indicates coenzyme Q; C, cytochrome C;
FAD ﬂavin adenine dinucelotide; FMN, ﬂavin mononucleotide; FE, heme iron; BH4, tetrahydrobiopterin; GPx Glutathione peroxidase; GSH Glutathione; GSSG Glutathione
disulﬁde; and G6PD Glucose-6-phosphate dehydrogenase.
Table 1
Enzymatic pathways: origin, reactive oxygen species (ROS), reactive nitrogen species (RNS) and their products [14,15].
Origin – Location of enzymatic pathway ROS & RNS potent oxidants Products – oxidized lipids and proteins
Mitochondrial respiratory chain Od2 , dOH Oxidized lipids, proteins, nucleic acids and autoxidation by
products.
Inﬂammatory macrophage membranous NAD(P)H oxidase Od2 , dOH, H2O2 Advanced lipoxidation end Products (ALE) Ortho o-tyrosine, Meta
m-tyrosine
Granular myeloperoxidase (MPO) Hypochlorous acid (HOCl) Tyr
dNO2
3-Chlorotyrosine dityrosine
dNO2 tyrosine (Nitrotyrosine)
Macrophage nitric oxide synthase ONOO dNO2 tyrosine (Nitrotyrosine)
Nitric oxide synthase (NOS) and constitutive nitric oxide
synthase (cNOS)
eNOS-dNO dNO2 tyrosine (Nitrotyrosine)
nNOS-dNO
dNOþOd2 -ONOO
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of diabetes [4,22]. Damage due to RMs is associated with
complex metabolic and structural changes in the body for
example, oxidation of low-density lipoproteins (Ox-LDL) which
are taken up by scavenger receptors in macrophages leading to
foam cell formation and atherosclerotic plaques [4,23]. ROS-
induced peroxidation of membrane lipids alters the structure
and ﬂuidity of biological membranes which ultimately affects
cellular function [24].
In T2DM, such activation of stress-sensitive pathways and
elevations in glucose and free fatty acid (FFA) levels lead to both
insulin resistance and impaired insulin secretion. In diabetic
arteries, endothelial dysfunction is a result of both insulin resis-
tance and hyperglycemia [21]. Diabetic dyslipidaemia is a result
of insulin resistance and hyperglycemia [21]. Hyperglycemia
seems to cause reduced expression of heparan sulfate proteogly-
can and perlecan on hepatocytes resulting in raised levels of
atherogenic cholesterol-enriched apolipoprotein B-containing
remnant particles [21]. Postprandial hyperglycemia may be more
predictive of atherosclerosis than fasting plasma glucose level or
hemoglobin A1c (HbA1c) [16,21]. Changes deﬁned lead to edema,
ischemia and hypoxia-induced neovascularization in the retina,
proteinuria, mesanglial matrix expansion and glomerulosclerosis
in the kidney and multifocal axonal degeneration in peripheral
nerves [21]. Diabetes related microvascular pathology is the
leading cause of blindness, end stage renal disease and a variety
of debilitating neuropathies [21]. The pathogenesis of athero-
sclerosis also begins with endothelial dysfunction. Atherosclerotic
macrovascular disease affects arteries that supply the heart, brain
and lower extremities. As a result, patients with diabetes have
a much higher risk of myocardial infarction, stroke and limb
amputation [22].
In healthy individuals both enzymatic and non-enzymatic
antioxidant defense play important roles in scavenging ROS and
RNS (Table 2). Impaired antioxidant defense increases oxidative
stress and contributes to the development of T2DM and diabetic
cardiovascular disease (CVD). Our recent studies have shown that
activity levels of SOD and GST were signiﬁcantly lower in T2DM
patients than in healthy subjects [25]. Od2 produces hydrogen
peroxide (H2O2) on its dismutation by copper superoxide dismu-
tase (Cu-SOD) and manganese-superoxide dismutase (Mn-SOD).
Hydrogen peroxide (H2O2) produces hydroxyl radical (dOH)
by reaction with reduced transition metals (Fe or Cu) i.e. fenton
reaction and can be metabolized to HOCl by MPO [10]. H2O2 is
converted to H2O and O2 by glutathione peroxidase (GSH-Px) or
catalase (CAT) in the mitochondria and lysosomes respectively.
The inner mitochondrial membrane also contains vitamin E which
is a powerful antioxidant as it can accept unpaired electrons to
produce a stable product [22].
Antioxidant genes and polymorphisms
Superoxide dismutase (SOD)
Once formed, Od2 is dismutated enzymatically to H2O2 and
oxygen by the SOD family of antioxidant enzymes which include
intracellular (Cu Zn-SOD), mitochondrial (Mn-SOD), and extracel-
lular (EC-SOD) enzymes also referred to as SOD types 1, 2 and
3 respectively [13]. An increase in Cu Zn-SOD (SOD1) expression
projects human smooth muscle cells against oxidative injury.
Ox-LDL causes an increase in the DNA binding activity of activator
protein-1 and NF-κB which is inhibited by Cu Zn-SOD
Fig. 2. Schematic representation of oxidative stress and the pathways leading to T2DM and its complications. Reactive oxygen species (ROS), reactive nitrogen species (RNS)
and oxidative stress induced by elevations in glucose and free fatty acid (FFA) levels play a key role in causing insulin resistance and β-cell dysfunction by activating stress-
sensitive signaling pathways. The proposed sequences of events include other stress pathways such as, increased production of advanced glycosylated end (AGE) products,
sorbitol, cytokines, prostanoids and hexosamines. ROS and RNS play a key role in the pathogenesis of diabetes by inﬂicting macromolecular damage. ROS also function as
signaling molecules to activate several stress-sensitive pathways such as nuclear factor kappa-light-chain-enhancer of activated cells (NF-kB), p38 class of mitogen activated
protein kinases (P38MAPK), janus kinase/signal transducer and activator of transcription (JAK/STAT) by elevations in glucose and possibly FFA levels leading to both insulin
resistance and impaired insulin secretion.
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overexpression. Cu Zn-SOD (SOD1) gene is located on chromosome
4p15.1–15.3 while Mn-SOD (SOD2) gene is located on chromosome
6q25. A functional polymorphism in exon 2 of SOD2 gene A16V (C/
T) (rs4880) was identiﬁed that resulted in structural alterations in
the mitochondrial targeting domain, implicating its decreased
antioxidant potential to limited post-transcriptional transport.
The substitution from valine to alanine was shown to induce a
30–40% increase in Mn-SOD activity in mitochondria resulting in
reduced risk of coronary artery disease (CAD) and acute myocar-
dial infarction (AMI) [26]. Individuals harboring the valine variant
had an increased carotid intima-to-media thickness (IMT) and
were at increased risk for CAD and AMI [27]. Increased oxidative
stress is the leading cause of post-translational covalent modiﬁca-
tions in SOD e.g. nitration, phosphorylation, glutathionylaion,
and glycation which results in decreased enzyme activity [28].
Polymorphic conditions of SOD1 35 A/C (rs2234694) and SOD2
A16V (C/T) showed that serum SOD activity was higher in indivi-
duals with ‘CC’ genotype than ‘TT’ genotype of SOD2 gene and
higher in ‘AA’ as compared to ‘CC’ genotype of SOD1 gene. Better
diabetes control was found in patients with ‘CC’ genotype of SOD2
gene. Signiﬁcantly different allele and genotype frequencies of SOD2
gene polymorphism were found among T2DM patients with and
without macroangiopathy, diabetic retinopathy in Chinese, diabetic
macular edema (DME) and albuminuria in Koreans [29–31].
EC-SOD (SOD3) is bound to matrix and EC proteoglycans.
EC-SOD (SOD3) gene is located on chromosome 21q22.11. Clinical
studies have shown a decrease in EC-SOD activity in aged, African–
Americans with hypertension, patients with vasospastic angina,
thoracic aortic aneurysm and calciﬁed aortic stenosis. Serum SOD
activity was signiﬁcantly decreased in T2DM subjects compared to
control subjects [32,33]. The variant R213G in the heparin-binding
domain of EC-SOD has been linked to cardiovascular disease risk.
This polymorphism was linked to increased risk of ischemic heart
disease in a Danish case control study as well [34].
Catalase
Catalase (CAT) is present in peroxisomes and exists as a
dumbell-shaped tetramer of four identical subunits. It rapidly
catalyzes the decomposition of hydrogen peroxide into less
reactive oxygen and water molecules. CAT deﬁciency was known
to lead to the development of T2DM [35,36]. CAT gene is located on
chromosome 11p13. Exon 2 and neighboring introns of the CAT
gene were thought to be mutation hot spots for T2DM suscept-
ibility [37,38]. Under conditions of oxidative stress, modiﬁcation of
cystein to cysteic acid leads to tyrosyl nitration of catalase and
decreased activity [39,40]. The exon 9-262C/T polymorphism in
CAT gene was examined in types 1, 2 and gestational diabetes (GD)
and complications such as diabetic retinopathy (DR), diabetic
nephropathy (DN), ischemic heart disease (IHD) and CVD [41].
This functional polymorphism also contributed to the develop-
ment of T2DM and its complications [42,43]. ‘AT’ genotype of
21A/T polymorphism of CAT gene may increase the risk of T2DM
in north Indians [44].
Glutathione peroxidases
Glutathione peroxidases (GPx) are selenocysteine-containing
enzymes that catalyze the reduction of H2O2 and lipid hydroper-
oxides to H2O and lipid alcohols respectively in a reaction that
utilizes glutathione (GSH) as a reducing co-substrate [41]. GPx may
also function as ONOO reductase. There are 5 known forms of
GPx: cellular (GPx-1), gastrointestinal (GPx-2), plasma (GPx-3),
phospholipid (GPx-4), and sperm (snGPx). The importance of GPx
family of antioxidant enzymes limits the oxidative risk for ather-
othrombosis. GPx-1 is an ubiquitous antioxidant enzyme whose
deﬁciency has been shown to promote endothelial dysfunction,
heart failure and abnormal structural changes in vasculature and
myocardium [49]. Interestingly, hyperhomocystinemia appears to
Table 2
Antioxidants in catalytic/enzymatic inactivation of free radicals and non-enzymatic antioxidants [14,15].
Enzymatic antioxidants Location Enzymatic action
Super Oxide Dismutase
(SOD) types:
(a) EC-SOD (extracellular)
(b) Mn-SOD (mitochondrial)
(c) Cu-Zn-SOD
(intracellular)
Mitochondria Od2 þSOD-H2O2þO2
Catalase Peroxisome 2H2O2þcatalase-2H2OþO2
Glutathione Peroxidase and
interrelated actions:
(a) Glutamyl-cysteinyl-
glycine tripeptide
(b) Glutathione peroxidase
(c) Glutathione reductase
Mitochondria/Cytosol
glutathione reduced – SH to the oxidized disulﬁde GSSG
GSHþ2H2O2-GSSGþH2OþO2
[GSSG-GSH] at the expense of [NADH-NADþ] and/or [NAD(P)H-NAD(P)þ]
Nitric Oxide Synthase (NOS)
types:
(a) eNOS (endothelial NOS)
(b) nNOS (neuronal NOS)
(c) iNOS (inducible-
inﬂammatory NOS)
Membrane isoforms (a) Endothelial dNO is a scavenger of ROS and acts as a chain breaking antioxidant for
scavenging ROS.
(b) Good dNO.
(c) dNO Good in host defense and bad in chronic inﬂammation, ischemia – ischemia
reperfusion injury, acute and chronic as in autoimmunity – T1DM.
Nonenzymatic antioxidants Location Enzymatic Action
(a) Uric acid.
(b) Vitamin A, Vitamin C,
Vitamin E.
(c) Thiols.
Apoproteins types:
Ceruloplasmin and
transferring
Bind copper and iron in forms participate in
the Fenton reaction which cannot
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enhance vascular oxidative stress and atherothrombosis, in part by
suppressing expression of the GPx-1 gene which is located on
chromosome 3p21.3. Erythrocyte GPx-1 activity and association of
GPx-1 genotypes was shown as independent determinants of
cardiovascular risk and CAD [50]. A polyalanine sequence poly-
morphism in exon 1 of GPx-1 gene produces 3 alleles with 5, 6, or
7 alanine repeats. Men with at least one 6-alanine repeat had
signiﬁcantly increased risk of CAD.
The Pro198Leu C/T polymorphism in GPx-1 gene increased
carotid intima-media thickness (IMT), prevalence of cardiovascular
and peripheral vascular disease in Japanese patients with T2DM
[41,51]. Out of a large number of factors mediating atherosclerotic
risk in plasma, focus lays on GPx-3, the essential extracellular
peroxidase and its role in modulating oxidative stress. Deﬁciency
of GPx-3 was associated with decreased nitric oxide bioavailability
and increased platelet dependent thrombosis. There was a reduc-
tion in plasma GPx-3 activity with increased platelet activation
and cerebrovascular arterial thrombosis [52,53]. GPx-3 promoter
revealed seven polymorphisms that are tightly linked and form
two novel haplotypes, out of which one was associated with
hypoxic conditions, arterial thrombotic stroke and cerebral venous
thrombosis [45].
Over expression of GPx-4 reduces oxidized phospholipids,
cholesterol hydroperoxides as well as proinﬂammatory lipid per-
oxides generated by LPO and COX thereby decreasing vascular
oxidative stress and progression of atherosclerosis [54].
Glutathione-S-transferases
The glutathione-S-transferases (GSTs) are dimeric cytosolic
xenobiotic-metabolizing enzymes that catalyze the conjugation
of an active xenobiotic to GSH, an endogenous water-soluble
substrate and detoxify reactive electrophiles such as those con-
tained in tobacco smoke. In addition to their catalytic role in
detoxiﬁcation, GSTs were also found to possess selenium-
independent peroxidase activity with hydroperoxides, steroid
isomerization capacity, binding and transport of bilirubin, heme,
bile salts and steroids in a process that is associated with a
decrease in enzymatic activity [55]. Several studies have found
an association between GST polymorphisms and decreased enzy-
matic activity and atherosclerosis. Elevated levels of plaque DNA
damage as well as levels of inﬂammatory markers such as
C-reactive protein (CRP), ﬁbrinogen and adhesion molecules were
detected in individuals with GST M1n0 null allele.
GST M1, T1 and P1 have been reported to be involved in T2DM
development and various diabetes related complications [48,56–
59]. Our present study indicates that individually Val105Val of
GSTP1 gene and multiple combinations GST isoforms increase the
risk of having T2DM in north Indian population [44]. Microsomal
GST3 encoded byMGST3 gene, which maps to chromosome 1q23 is
a potential susceptibility gene linked to T2DM in Pima Indians,
Caucasian and Chinese populations [60].
Nitric oxide synthase
Nitric oxide (NO) plays a fundamental role in the regulation of
endothelial function and vascular tone in many organs including
kidney. It inhibits platelet aggregation, leukocyte adhesion to
vascular endothelium and oxidation of low-density lipoprotein
(LDL) [46]. Upon release, NO diffuses rapidly through the cell
membrane and relaxes neighboring vascular smooth cells through
the production of cyclic guanine 3050-monophosphate (cGMP).
cGMP then activates the protein kinase G family, leading to a
cascade of responses at the levels of transcription and translation.
Table 3
Antioxidant gene polymorphisms in T2DM.
Enzyme Location Locus Polymorphisms Disease risk Post-translational
modiﬁcation(s)
References
SODs Cu,Zn-
SOD
(SOD1)
Cytosol, nuclear, and
lysosomes
4p15.3–
p15.1
None associated with↑↑disease risk N/A Tryptophan nitration of
Trp32
[30]
Mn-SOD
(SOD 2)
Mitochondria 6q25.3 Ala16→Val ↑Carotid intima-
media thickness
Tyrosine nitration of
Tyr34, Tyr45, Tyr193
[30]
EC-SOD
(SOD 3)
Bound to matrix and
EC proteoglycans
21q22.11 None associated with↑↑disease risk N/A None reported [32,33]
Catalase Peroxisomes 11p13 GA insertion in exon 2 G insertion in exon 2 T→G
substitution in intron 7 -262C→T substitution in exon 9
↑Diabetes mellitus Tyrosine nitration [40,41,44]
↑Homocysteine Cys377
↑ Vascular oxidant
stress
Chlorination
Carbonylation
GPx's Intracellular,
membranebound
3p21.3 Pro198→Leu ↑ Carotid intima-
media thickness
None reported [41]
GPx-1 ↑ Peripheral
arterial disease
↑ Coronary
artery disease
↑ Thoracic aortic
aneurysm
GPx-3 Extracellular 5q23 plasma7-SNP promoter haplotyope ↑ Stroke None reported [45]
↑ Cerebral venous
thrombosis
eNOS Extracellular 7q36 −786 T/C, Glu298Asp(rs1799983), 27 bp VNTR (intron 4) ↑ Coronary artery
disease
None reported [46]
↑Hypertension
iNOS Intracellular 17p13.1 Ser608Leu (rs2297518) – No association [47]
GST Intracellular,
Cytosolic
M1*0 and T1*1 alleles ↑ Coronary artery
disease
Tyrosine nitration
Carbonylation
[44,48]
GST M1 1p13.3 ↑ Peripheral
arterial disease
GST T1 22q11.23
GST P1 11q13
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Inducible nitric oxide synthase (NOSI/iNOS), neural NOS (NOS
II/nNOS) and endothelial NOS (NOSIII/eNOS) are the three isoforms
of NOS.
Clinically, eNOS uncoupling has been associated with hyperten-
sion, diabetes mellitus, hypercholesterolemia and atherosclerosis
[61]. Impairment of NO production causes endothelial dysfunction
which contributes to the development of insulin resistance, T2DM,
chronic renal failure and cardiovascular complications including
hypertension and hypercholesterolemia [62].
eNOS or NOSIII gene, mapped to chromosome 7q36 is highly
polymorphic and several studies have been undertaken to inves-
tigate the potential association of polymorphisms and risk of
atherothrombotic vascular disease in Caucasian and Asian popula-
tions. SNPs in the promoter region (786 T/C), G/T substitution
at nucleotide 894 in exon 7 leading to an amino acid change
(Glu298Asp) and a 27 bp variable number of tandem repeats
(27 bp-VNTR) in intron 4 have received much attention because
of their functional relevance to eNOS activity and association with
cardiovascular and renal diseases [46]. The Glu298Asp gene
polymorphism is responsible for a decrease in basal NO production
and increased frequency of hypertension [63]. Additionally, eNOS
Glu298Asp can interact with gene polymorphisms of other endo-
genous antioxidant enzymes in T2DM patients [14,15,62,64].
In atherosclerosis, vascular smooth muscle cells, monocytes,
macrophages, and dendritic cells all express iNOS. Induction of
iNOS may occur following exposure to inﬂammatory cytokines,
including interleukin-1β (IL-1 β), interferon-γ (INF-γ), and tumor
necrosis factor-α (TNF-α). In contrast to eNOS, iNOS binds Ca2þ/
calmodulin tightly and does not require an increase in intracellular
Ca2þ for activation [65]. The presence of iNOS localized to
macrophages and vascular smooth muscle cells was found to
colocalize with oxidized lipid and protein derivatives found in
atherosclerotic plaques [66]. No association of eNOS Glu298Asp
(rs1799983), eNOS 4a/b and iNOS Ser608Leu (rs2297518) poly-
morphisms was found in T2DM patients with diabetic nephro-
pathy [47]. It has therefore been widely used as a biomarker for
oxidative stress and T2DM.
Conclusions
T2DM and oxidative stress have a clinical and genetic correla-
tion which needs to be established to a greater extent. The overall
play of the RMs has shown to be the lead cause of late onset
insulin resistance. These RMs are generated inside the body of
normal individuals in a scheduled manner and are in feedback
control with the antioxidant system. Glycemic load and RMs are
highly interrelated leading to various harmful molecular mechan-
isms implicated in glucose-mediated vascular damage such as
increased polyol pathway ﬂux; increased production of advanced
glycation end-product (AGE); activation of protein kinase C (PKC)
isoforms, sorbitol, cytokines and prostanoids along with increased
hexosamine pathway ﬂux. These pathways lead to increased
expression of other signaling pathways which result in insulin
resistance and T2DM. This review was undertaken to understand
the role of RMs in T2DM and provides a lead for future research in
identifying antioxidant gene variants and risk genotypes in popu-
lations of different ethnicity (Table 3).
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